Related Experiment Videos

The STAT3 oncogene as a predictive marker of drug resistance

Benjamin Barré1, Arnaud Vigneron, Neil Perkins

  • 1School of Life Sciences, Division of Gene Regulation and Expression, Dundee, DD1 5EH, Scotland, UK.

Trends in Molecular Medicine
|November 23, 2006
PubMed

Insights

Constitutive activation of signal transducer and activator of transcription 3 (STAT3) promotes cancer cell growth and survival. STAT3 activation may also cause intrinsic drug resistance, suggesting STAT3 as a therapeutic target for chemotherapy-resistant tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Constitutive activation of signal transducer and activator of transcription 3 (STAT3) is implicated in various cancers.
  • STAT3 promotes cell transformation by inhibiting apoptosis and activating the cell cycle.
  • STAT3 influences cell survival by upregulating pro-survival proteins and downregulating tumor suppressors.

Purpose of the Study:

  • To investigate the role of STAT3 in intrinsic drug resistance in tumors.
  • To determine if STAT3 activation contributes to resistance to chemotherapeutic agents.
  • To explore the potential of targeting the STAT3 pathway to restore chemosensitivity.

Main Methods:

  • The study proposes a hypothesis based on existing literature regarding STAT3's role in cancer.
  • The methodology involves analyzing the correlation between STAT3 activation and chemotherapy response.
  • Potential therapeutic strategies targeting the STAT3 pathway are discussed.

Main Results:

  • The hypothesis suggests that STAT3-expressing tumors exhibit intrinsic resistance to chemotherapy.
  • Detection of activated STAT3 could identify patient subsets unresponsive to standard chemotherapy.
  • Interference with the STAT3 pathway may re-sensitize tumors to anticancer drugs.

Conclusions:

  • STAT3 activation is a potential driver of intrinsic chemoresistance in cancer.
  • Identifying activated STAT3 could guide personalized treatment strategies.
  • Targeting STAT3 represents a promising approach to overcome drug resistance in cancer therapy.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...